Triastek's 3D Printed Gastric Retention Product T22 Receives FDA Clearance of IND Application
31. Januar 2024 08:00 ET
|
Triastek, Inc.
NANJING, CHINA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Triastek's 3D printed gastric retention product T22 received IND clearance from the FDA, becoming the world's first 3D printed gastric retention...
Triastek Completes USD 20.4 Million Pre-C Funding Round to Accelerate Commercialization of 3D Printing Pharmaceutical Technology and Products
28. September 2023 06:55 ET
|
Triastek, Inc.
Nanjing, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Triastek, Inc. ("Triastek") today announced the completion of a USD 20.4 million Pre-C financing round. This milestone marks a significant step in the...
三迭紀完成1.5億元Pre-C輪融資 加速推進3D打印藥物商業化進程
28. September 2023 06:04 ET
|
Triastek, Inc.
Nanjing, Sept. 28, 2023 (GLOBE NEWSWIRE) -- 9月28日，南京三迭紀醫藥科技有限公司（下稱：三迭紀）宣佈完成1.5億元人民幣Pre-C輪融資，主要用於加速3D打印藥物管線的臨牀研究和3D打印藥物技術的商業化進程。本輪融資由國鑫投資領投，高脈聯合家族辦公室和老股東東富龍科技集團股份有限公司董事長鄭效東先生跟投，華興資本擔任本輪融資的獨家財務顧問。 ...
Triastek Completes USD 20.4 Million Pre-C Funding Round to Accelerate Commercialization of 3D Printing Pharmaceutical Technology and Products
28. September 2023 06:04 ET
|
Triastek, Inc.
Nanjing, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Triastek, Inc. ("Triastek") today announced the completion of a USD 20.4 million Pre-C financing round. This milestone marks a significant step in the...
Triastek Reports Positive FIH Results from Study of T21, a 3D Printed Oral Treatment for Moderate to Severe Ulcerative Colitis
21. Juli 2023 04:03 ET
|
Triastek, Inc.
The study verified the ability for Triastek's 3D Microstructure for Colon Targeting (3DμS-CT) to precisely target and release medication in the colonNanjing, July 21, 2023 (GLOBE NEWSWIRE) --...
Triastek Reports Positive FIH Results from Study of T21, a 3D Printed Oral Treatment for Moderate to Severe Ulcerative Colitis
20. Juli 2023 07:00 ET
|
Triastek, Inc.
The study verified the ability for Triastek's 3D Microstructure for Colon Targeting (3DμS-CT) to precisely target and release medication in the colon Nanjing, July 20, 2023 (GLOBE NEWSWIRE) --...
三迭紀T21 FIH結果出爐 獨創技術平台可行性得以驗證
19. Juli 2023 23:45 ET
|
Triastek, Inc.
南京, July 20, 2023 (GLOBE NEWSWIRE) -- 南京三迭紀醫藥科技有限公司（簡稱“三迭紀”，英文名Triastek）宣布，公司自主研發的第三款3D打印藥物產品T21已完成全球首次人體試驗（First in human,...
三迭纪榮獲2023 TCT Awards最佳醫療應用獎 以MED技術引領數字化製藥
08. Juni 2023 04:18 ET
|
Triastek, Inc.
南京, June 08, 2023 (GLOBE NEWSWIRE) -- 增材製造行業權威性年度獎項2023 TCT Awards在英國伯明翰揭曉，三迭紀榮獲「最佳醫療應用獎」，成為首個獲得該獎項的藥物3D打印公司，同時亦是首個榮獲該獎項的中國企業。 TCT...
Triastek Honored with 2023 Healthcare Application Award at the TCT Awards Ceremony – Triastek’s Melt Extrusion Deposition (MED®) 3D printing technology voted best 3D printing technology in the healthcare sector
08. Juni 2023 04:18 ET
|
Triastek, Inc.
Nanjing, June 08, 2023 (GLOBE NEWSWIRE) -- Triastek, Inc. ("Triastek"), a global healthcare company developing medicines with proprietary, pioneering 3D printing technology, today announced they...
Triastek Honored with 2023 Healthcare Application Award at the TCT Awards Ceremony – Triastek’s Melt Extrusion Deposition (MED®) 3D printing technology voted best 3D printing technology in the healthcare sector
08. Juni 2023 04:01 ET
|
Triastek, Inc.
Nanjing, June 08, 2023 (GLOBE NEWSWIRE) -- Triastek, Inc. ("Triastek"), a global healthcare company developing medicines with proprietary, pioneering 3D printing technology, today announced they...